Vagal Nerve Stimulation in Irritable Bowel Syndrome

NCT ID: NCT06090110

Last Updated: 2024-08-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are:

* To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment.
* To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately.
* To evaluate the effect of treatment on quality of life
* To evaluate the effect of treatment on depression
* To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed.

In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode.

Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

transcutaneous auricular vagal nerve stimulation, for 8 weeks at least one hour a day

Group Type ACTIVE_COMPARATOR

Vagal Nerve Stimulation

Intervention Type DEVICE

Transcutaneous Auricular Vagal Nerve Stimulation

placebo

sham stimulation with a non-conducting electrode, for 8 weeks at least one hour a day

Group Type PLACEBO_COMPARATOR

Sham stimulation

Intervention Type DEVICE

Sham stimulation with a non-conduction electrode

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vagal Nerve Stimulation

Transcutaneous Auricular Vagal Nerve Stimulation

Intervention Type DEVICE

Sham stimulation

Sham stimulation with a non-conduction electrode

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of IBS according to Rome IV criteria (3), as follows:
* Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria:
* Related to defecation.
* Associated with a change in stool frequency.
* Associated with a change in stool from (appearance).
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
* Age between 18 and 75 years;
* Ability to understand and speak the Dutch language.
* Ability to understand how to utilize the ESM application.

Exclusion Criteria

* A history of abdominal surgery, except for uncomplicated appendectomy, laparoscopic cholecystectomy and hysterectomy is present or otherwise based on the principal investigator's judgement.
* Presence of metallic prostheses, pacemakers, metal clips on blood vessels, metal parts in the eye, an intrauterine device (with the exception of the Mirena IUD), metal braces, facial tattoos and/or metal objects.
* History of major head trauma or head/brain surgery
* History of claustrophobia
* Pregnancy, lactation, intention to become pregnant during the study period
* Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional or hierarchical position with regards to any of the study team members or their department.
* If the subject has a cardiac arrhythmia, the attending physician will be consulted before participation.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Keszthelyi

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University

Maastricht, Limburg, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kimberly Hawinkels

Role: CONTACT

0883887808

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Kimberly Hawinkels

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL84720.068.23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cerebral Cortical Influences on Autonomic Function
NCT03869372 ACTIVE_NOT_RECRUITING NA